Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.

Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

Substitution occurred or is permitted with another product that is a:

• pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
• pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration

Examples:

• Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
• Pharmaceutical equivalent: Lisonpril for Zestril

Substitution occurred or is permitted between equivalent Brands but not Generics

Examples:

• Zestril for Prinivil
• Coumadin for Jantoven

Substitution occurred or is permitted between equivalent Generics but not Brands

Examples:

• Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)

Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

Examples:

• ranitidine for Tagamet

Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

Examples:

• Zantac for Tagamet

Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

Examples:

• Ranitidine for cimetidine

This substitution was performed or is permitted based on formulary guidelines.

No substitution occurred or is permitted.